Notice: This company has been marked as potentially delisted and may not be actively trading. Bioblast Pharma (ORPN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends ORPN vs. GLMD, SONN, SXTC, ONCT, PBLA, TRVN, CYTO, TFFP, ASLN, and PXMDShould you be buying Bioblast Pharma stock or one of its competitors? The main competitors of Bioblast Pharma include Galmed Pharmaceuticals (GLMD), Sonnet BioTherapeutics (SONN), China SXT Pharmaceuticals (SXTC), Oncternal Therapeutics (ONCT), Panbela Therapeutics (PBLA), Trevena (TRVN), Altamira Therapeutics (CYTO), TFF Pharmaceuticals (TFFP), ASLAN Pharmaceuticals (ASLN), and PaxMedica (PXMD). These companies are all part of the "medical" sector. Bioblast Pharma vs. Galmed Pharmaceuticals Sonnet BioTherapeutics China SXT Pharmaceuticals Oncternal Therapeutics Panbela Therapeutics Trevena Altamira Therapeutics TFF Pharmaceuticals ASLAN Pharmaceuticals PaxMedica Galmed Pharmaceuticals (NASDAQ:GLMD) and Bioblast Pharma (NASDAQ:ORPN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment. Does the MarketBeat Community prefer GLMD or ORPN? Galmed Pharmaceuticals received 230 more outperform votes than Bioblast Pharma when rated by MarketBeat users. However, 78.23% of users gave Bioblast Pharma an outperform vote while only 63.69% of users gave Galmed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformGalmed PharmaceuticalsOutperform Votes44263.69% Underperform Votes25236.31% Bioblast PharmaOutperform Votes21278.23% Underperform Votes5921.77% Which has better valuation and earnings, GLMD or ORPN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalmed PharmaceuticalsN/AN/A-$6.91M-$16.66-0.17Bioblast PharmaN/AN/A-$5.94MN/AN/A Which has more risk & volatility, GLMD or ORPN? Galmed Pharmaceuticals has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Bioblast Pharma has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Does the media refer more to GLMD or ORPN? In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Bioblast Pharma. MarketBeat recorded 2 mentions for Galmed Pharmaceuticals and 0 mentions for Bioblast Pharma. Galmed Pharmaceuticals' average media sentiment score of 1.43 beat Bioblast Pharma's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Galmed Pharmaceuticals Positive Bioblast Pharma Neutral Do insiders & institutionals believe in GLMD or ORPN? 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Bioblast Pharma shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is GLMD or ORPN more profitable? Bioblast Pharma's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Galmed PharmaceuticalsN/A -28.75% -24.98% Bioblast Pharma N/A N/A N/A SummaryGalmed Pharmaceuticals and Bioblast Pharma tied by winning 5 of the 10 factors compared between the two stocks. Ad InvestorPlaceThe 2024 TECH RESETAre we on the edge of the biggest ‘TECH RESET’ in decades?Click here for the step-by-step details Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORPN vs. The Competition Export to ExcelMetricBioblast PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$546,000.00$6.75B$5.23B$9.01BDividend YieldN/A7.94%5.34%4.01%P/E RatioN/A7.95114.7516.22Price / SalesN/A327.811,286.4982.49Price / CashN/A59.1741.8638.55Price / Book0.175.574.884.92Net Income-$5.94M$152.27M$119.50M$224.48M Bioblast Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORPNBioblast PharmaN/A$1.30+20.4%N/A-40.0%$546,000.00N/A0.00N/AGap UpHigh Trading VolumeGLMDGalmed Pharmaceuticals2.4123 of 5 stars$2.94+2.8%N/A-34.7%$1.88MN/A-0.1720Positive NewsSONNSonnet BioTherapeutics2.8559 of 5 stars$2.61+1.6%$30.00+1,049.4%+66.2%$1.78M$55,881.000.0012Positive NewsGap UpSXTCChina SXT Pharmaceuticals1.2155 of 5 stars$0.39-2.4%N/A-84.8%$1.59M$1.93M0.0090Positive NewsGap UpONCTOncternal Therapeutics3.4028 of 5 stars$0.53-23.3%$20.00+3,697.9%-92.3%$1.56M$790,000.00-0.0530High Trading VolumePBLAPanbela Therapeutics0.7187 of 5 stars$0.31-5.6%$500.00+163,834.4%-97.2%$1.48MN/A0.007Gap DownTRVNTrevena0.8088 of 5 stars$1.70+0.6%$5.00+194.1%-88.5%$1.46M$3.12M-0.0440CYTOAltamira Therapeutics1.2386 of 5 stars$0.43-1.0%N/A-92.5%$1.45M$320,000.000.0020Gap DownTFFPTFF Pharmaceuticals2.0676 of 5 stars$0.32-4.5%$44.00+13,564.6%-96.5%$1.43M$-70,983.00-0.0519Positive NewsGap DownHigh Trading VolumeASLNASLAN PharmaceuticalsN/A$0.60flat$76.00+12,566.7%N/A$1.23M$12M-0.0330PXMDPaxMedicaN/A$0.11+11.6%$3.00+2,730.2%-89.0%$1.20MN/A0.002Gap Down Related Companies and Tools Related Companies Galmed Pharmaceuticals Competitors Sonnet BioTherapeutics Competitors China SXT Pharmaceuticals Competitors Oncternal Therapeutics Competitors Panbela Therapeutics Competitors Trevena Competitors Altamira Therapeutics Competitors TFF Pharmaceuticals Competitors ASLAN Pharmaceuticals Competitors PaxMedica Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORPN) was last updated on 12/4/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredHas World War III already started?As global tensions are rising, so does the potential of direct conflict between the US and China. That's wh...Behind the Markets | SponsoredMeet the NYSE traded company behind a potentially blockbuster antiviral drugThis public company’s one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market Imag...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
